Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Payables (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Payables for 6 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Payables rose 234.12% year-over-year to $6.6 million, compared with a TTM value of $6.6 million through Dec 2025, up 234.12%, and an annual FY2025 reading of $6.6 million, up 234.12% over the prior year.
  • Payables was $6.6 million for Q4 2025 at SAB Biotherapeutics, down from $6.9 million in the prior quarter.
  • Across five years, Payables topped out at $10.7 million in Q4 2022 and bottomed at $1.5 million in Q2 2023.
  • Average Payables over 5 years is $5.2 million, with a median of $6.0 million recorded in 2022.
  • The sharpest move saw Payables crashed 85.05% in 2023, then skyrocketed 323.42% in 2024.
  • Year by year, Payables stood at $6.3 million in 2021, then skyrocketed by 70.91% to $10.7 million in 2022, then plummeted by 81.32% to $2.0 million in 2023, then dropped by 1.31% to $2.0 million in 2024, then soared by 234.12% to $6.6 million in 2025.
  • Business Quant data shows Payables for SABS at $6.6 million in Q4 2025, $6.9 million in Q3 2025, and $2.6 million in Q2 2025.